Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Immunomedics disclosed in its fiscal 3Q13 earnings for the period ended March 31 that Takeda's Nycomed company
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury